ACTR-41. AN ARGUMENT THAT MORE ADJUVANT TEMOZOLOMIDE THERAPY IS BETTER FOR GLIOMA PATIENTS

Current guidelines for adjuvant temozolomide (TMZ) treatment of glioma patients advocates 6 to 12 monthly cycles. Is that best? Will patients who receive > 12 cycles live longer? To find out, we conducted a 10-year (2006–2016) chart review of 1300 glioma patients treated at NorCal Kaiser Permanen...

Full description

Saved in:
Bibliographic Details
Published in:Neuro Oncol
Main Authors: Levin, Victor, Patel, Alyssa, Le, Amy, Thomas, Piia, Scott, Peak
Format: Artigo
Language:Inglês
Published: Oxford University Press 2019
Subjects:
Adult Clinical Trials - Non-Immunologic
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847321/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.083
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items